Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRB Spruce Biosciences, Inc.

Trading 07-10 13:21:26 EDT

49.93

-1.81

-3.50%

High51.98	Low49.26	Vol24.27K
Open51.38	D1 Closing51.74	Amplitude5.25%
Mkt Cap137.42M	Tradable Cap132.48M	Total Shares2.75M
T/O1.21M	T/O Rate0.91%	Tradable Shares2.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":49.93,"timestamp":1783704070219,"preClose":51.74,"halted":0,"volume":24273,"delay":0,"changeRate":-0.03498260533436417,"floatShares":2653399,"shares":2752300,"eps":-38.620026,"marketStatus":"Trading","change":-1.81,"latestTime":"07-10 13:21:26 EDT","open":51.38,"high":51.975,"low":49.26,"amount":1210566.989178,"amplitude":0.052474,"askPrice":51.02,"askSize":117,"bidPrice":49.72,"bidSize":105,"shortable":3,"etf":0,"ttmEps":-38.620026,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1783713600000},"marketStatusCode":2,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":51.74,"preHourTrading":{"tag":"盘前","latestPrice":51,"preClose":51.74,"latestTime":"08:17 EDT","volume":1,"amount":51,"timestamp":1783685859401,"change":-0.74,"changeRate":-0.014302,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":51.74,"preClose":51.74,"latestTime":"16:52 EDT","volume":32,"amount":1654.2,"timestamp":1783630343762,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.69363,"impliedVol":0.883,"impliedVolPercentile":0.95},"requestUrl":"/m/hq/s/SPRB/tweets","defaultTab":"tweets","newsList":[{"id":"2647371579","title":"Spruce Biosciences joins Russell 3000 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371579?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:15","pubTimestamp":1782735324,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (SPRB) announced that it has been added as a member of the Russell 3000 Index, effective with the opening of U.S. equity markets...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-joins-russell-3000-index-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-joins-russell-3000-index-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645697024","title":"Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2645697024","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645697024?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129640,"startTime":"0","endTime":"0","summary":"Spruce Biosciences named Agnieszka “AJ” Jurecka vice president, medical affairs, as it prepares for a potential U.S. FDA decision on tralesinidase alfa.She most recently served as chief medical officer at a seed-stage gene therapy company developing CNS-directed therapies for lysosomal gene defects.Jurecka previously led rare-disease programs at CoA Therapeutics and Ultragenyx, with earlier medical affairs roles at Shire, Synageva, Aegerion, and BioMarin.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6y6MPx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","SPRB","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BMRN","BK4566","BK4139","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024549","title":"Spruce Biosciences Appoints Agnieszka Jurecka, M.d., Ph.d., Mph, as Vice President, Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024549?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUAYKYPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643475732","title":"Spruce Biosciences Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2643475732","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643475732?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:42","pubTimestamp":1781613720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 08:42 ET (12:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643520383","title":"Spruce Biosciences names Eric Jordan as VP, Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643520383","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643520383?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:01","pubTimestamp":1781524901,"startTime":"0","endTime":"0","summary":"Spruce Biosciences named Eric Jordan vice president, marketing, as it prepares for a potential U.S. FDA approval and launch of TA-ERT.Jordan previously led marketing and launch planning for encaleret at BridgeBio.He earlier ran U.S. commercialization of Oxervate at Dompé Pharmaceuticals, helping build it into a $1 billion brand.Tina Gullotta joined as vice president, finance, corporate controller, tasked with scaling finance and reporting as Spruce moves toward commercialization.Gullotta was vice president, finance at Frontier Medicines, following senior finance roles at Sunesis Pharmaceuticals and Atara Biotherapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to genera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL7QcwGm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATRA","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643208045","title":"Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller","url":"https://stock-news.laohu8.com/highlight/detail?id=2643208045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643208045?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3TPD6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642498942","title":"Spruce Biosciences Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2642498942","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642498942?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:16","pubTimestamp":1781010960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 09:16 ET (13:16 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642699432","title":"Spruce Biosciences Reports Long-Term Data for Enzyme Replacement Therapy to Treat Genetic Disease MPS IIIB","url":"https://stock-news.laohu8.com/highlight/detail?id=2642699432","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642699432?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:45","pubTimestamp":1780955100,"startTime":"0","endTime":"0","summary":"Spruce Biosciences  said late Monday its long-term data for tralesinidase alfa enzyme replacement therapy in patients with fatal genetic disease Sanfilippo Syndrome Type B or MPS IIIB, demonstrated a rapid and durable reduction of heparan sulfate non-reducing end, which is a surrogate endpoint.Data also showed relatively preserved cognitive and non-cognitive outcomes, including communication and motor skills, over a six-year period, according to a statement.These findings support the therapy's potential as the first disease-modifying treatment option, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642343354","title":"Spruce Biosciences initiated with a Buy at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2642343354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642343354?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:26","pubTimestamp":1780950396,"startTime":"0","endTime":"0","summary":"JonesResearch analyst Catherine Novack initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $135 price target The firm says its va...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-initiated-with-a-buy-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-initiated-with-a-buy-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431494","title":"Spruce says long-term TA-ERT data presented at MPS Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431494?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:11","pubTimestamp":1780949487,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (SPRB) announced that data demonstrating the long-term benefit of tralesinidase alfa enzyme replacement therapy in patients with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-says-long-term-ta-ert-data-presented-at-mps-symposium-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-says-long-term-ta-ert-data-presented-at-mps-symposium-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642313774","title":"Spruce Biosciences reports six-year tralesinidase alfa data showing sustained biomarker reductions, stabilized cognition in MPS IIIB","url":"https://stock-news.laohu8.com/highlight/detail?id=2642313774","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642313774?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:05","pubTimestamp":1780949142,"startTime":"0","endTime":"0","summary":"Spruce Biosciences reports six-year tralesinidase alfa data showing sustained biomarker reductions, stabilized cognition in MPS IIIB. Spruce Biosciences reported long-term data for tralesinidase alfa enzyme replacement therapy in Sanfilippo syndrome type B, presented June 4-7, 2026.Results included data previously presented at the 22nd Annual WORLD Symposium, extending follow-up to as long as six years.Treatment was associated with sustained disease-biomarker improvement, with cognitive function and daily functioning preserved versus declines in untreated natural history patients.Imaging and organ assessments were consistent with stabilization of disease-related changes, supporting a potential disease-modifying profile.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLC4gpf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431354","title":"Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (Mps Iiib) Presented at the 18TH International Mps Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431354?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:05","pubTimestamp":1780949100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUA3BHBKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640956880","title":"Spruce Biosciences Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2640956880","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640956880?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:12","pubTimestamp":1780312320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 07:12 ET (11:12 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640495810","title":"Spruce Biosciences, Inc : H.c. Wainwright Cuts Target Price to $150 From $200","url":"https://stock-news.laohu8.com/highlight/detail?id=2640495810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640495810?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:14","pubTimestamp":1780308850,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN42902P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639619643","title":"Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2639619643","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639619643?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:41","pubTimestamp":1780000906,"startTime":"0","endTime":"0","summary":"May 28 (Reuters) - Spruce Biosciences, Inc ::*SPRUCE BIOSCIENCES ANNOUNCES DATA PRESENTATION AT THE 18TH INTERNATIONAL MPS SYMPOSIUM  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 28-MAY-202620:05:00.437 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nRSDbwpy1x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639861680","title":"Spruce Biosciences to present long-term tralesinidase alfa data in Sanfilippo syndrome Type B at International MPS Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2639861680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639861680?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:09","pubTimestamp":1779998976,"startTime":"0","endTime":"0","summary":"Spruce Biosciences flagged long-term data for tralesinidase alfa in Sanfilippo syndrome type B for presentation on June 6, 2026.Results will be presented in Florence at the 18th International MPS & Related Lysosomal Diseases Symposium.Study readout points to sustained disease-biomarker reduction with stabilization of cognition and brain gray matter volume over extended treatment.Update keeps the program positioned as a potential late-stage therapy option in a rare neurologic disorder with limited treatment choices.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL5JKhxh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639615762","title":"Spruce Biosciences Announces Data Presentation at the 18TH International Mps Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2639615762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639615762?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:05","pubTimestamp":1779998701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUAC67LFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638263596","title":"Spruce Biosciences to present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2638263596","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638263596?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:06","pubTimestamp":1779912398,"startTime":"0","endTime":"0","summary":"Spruce Biosciences management to present at the Jefferies Global Healthcare Conference on June 4, 2026 at 11:05 a.m. ET in New York.Company to hold one-on-one meetings at the BIO International Convention on June 24-25 in San Diego.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL8JKCFT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638768837","title":"Analysts’ Top Healthcare Picks: Spruce Biosciences (SPRB), CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638768837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638768837?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:40","pubTimestamp":1779885630,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spruce Biosciences (SPRB) and CG Oncology, Inc. (CGO...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spruce-biosciences-sprb-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spruce-biosciences-sprb-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","IE00BGHQF748.EUR","CG","BK4139","BK4585","CGON","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0029874061.USD","LU0128526141.USD","HCSG","SPRB","XBI","BK4137","LABU","XLV","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638523909","title":"Spruce Biosciences Stockholders Approve Directors and Annual Say-on-Pay","url":"https://stock-news.laohu8.com/highlight/detail?id=2638523909","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638523909?lang=en_us&edition=fundamental","pubTime":"2026-05-27 05:04","pubTimestamp":1779829461,"startTime":"0","endTime":"0","summary":"Spruce Biosciences ( ($SPRB) ) has shared an announcement. Spruce Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 21, 2026, i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-stockholders-approve-directors-and-annual-say-on-pay?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-stockholders-approve-directors-and-annual-say-on-pay?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0147},{"period":"1month","weight":0.0553},{"period":"3month","weight":-0.1869},{"period":"6month","weight":-0.3532},{"period":"1year","weight":710.6919},{"period":"ytd","weight":-0.406}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.190445},{"month":2,"riseRate":0.5,"avgChangeRate":-0.036118},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.209049},{"month":4,"riseRate":0,"avgChangeRate":-0.19428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.048966},{"month":6,"riseRate":0.5,"avgChangeRate":-0.057688},{"month":7,"riseRate":0.5,"avgChangeRate":0.067559},{"month":8,"riseRate":0.4,"avgChangeRate":0.028537},{"month":9,"riseRate":0.4,"avgChangeRate":-0.136102},{"month":10,"riseRate":0.4,"avgChangeRate":2.105377},{"month":11,"riseRate":0.5,"avgChangeRate":0.001192},{"month":12,"riseRate":0.333333,"avgChangeRate":0.217863}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}